Lyn peptide inhibitor
Based on 1 Customer Validation
Lyn peptide inhibitor (YGYRLRRKWEEKIPNP-NH2) is a potent, cell-permeable Lyn kinase inhibitor that inhibits Lyn-coupled signaling pathways associated with the IL-5 receptor while preserving the integrity of other signals. Lyn peptide inhibitor blocks the activation of Lyn and inhibits the binding of Lyn tyrosine kinase to the βc subunit of the IL-3/GM-CSF/IL-5 receptor. Lyn peptide inhibitor can be used in the research of eosinophilic diseases such as asthma and allergy.
For research use only. We do not sell to patients.
- Purity: 99.35%
- CAS No.: 222018-18-0
- Formula: C115H184N30O24
- Molecular Weight:2370.88
-
Storage:
Sealed storage, away from moisture.
Powder -80°C, 2 years , -20°C, 1 year* In solvent : -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture)
To place orders, for customer services and technical support, please contact: MedChemExpress USA
Tel: 609-228-6898 E-mail: [email protected] [email protected]
-
Biological Activity
-
Chemical Information
-
Solvent & Solubility
- Purity & Documentation
- References
-
Help & FAQs
Biological Activity
|
IL-5 |
IL-3 |
Lyn peptide inhibitor (20 μM; 2 h) specifically blocks the binding of Lyn kinase to the βc subunit of IL-5/GM-CSF receptor in purified human eosinophils, without altering the binding of Jak2 to βc[1].
Lyn peptide inhibitor (5-20 μM; 2 h) dose-dependently blocks IL-5-induced cellular protein tyrosine phosphorylation and Lyn kinase activation in purified human eosinophils, without inhibiting Jak2 kinase activation[1].
N-stearoylated Lyn peptide inhibitor (20 μM; 2 h) blocks IL-5/IL-3-induced differentiation of mouse bone marrow cells into eosinophils. A significant inhibitory effect is observed on day 3 of culture, and this inhibitory effect persists until day 10 of culture[1]
N-stearoylated Lyn peptide inhibitor (2-20 μM; 2 h) reduces IL-5-induced viability of purified human eosinophils in a dose-dependent manner, with significant decreases in cell viability observed at concentrations of 10 μM and 20 μM[1].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
-
Animal Model:BALB/c (OVA-sensitized)[1]
-
Dosage:2 mmol (≈0.5 mg)
-
Administration:intrabronchial; single dose
-
Result:Reduced eosinophil influx into BAL fluid to a mean count of ~2.5 × 105 cells.
Showed no significant differences in lymphocyte or macrophage counts compared to controls.
Chemical Information
-
CAS No. 222018-18-0
-
Appearance Solid
-
Molecular Weight 2370.88
-
Formula C115H184N30O24
-
Color White to off-white
-
Sequence
{Stearoyl}-Tyr-Gly-Tyr-Arg-Leu-Arg-Arg-Lys-Trp-Glu-Glu-Lys-Ile-Pro-Asn-Pro-NH2
-
Sequence Shortening
{Stearoyl}-YGYRLRRKWEEKIPNP-NH2
-
Shipping
Room temperature in continental US; may vary elsewhere.
-
Storage
Sealed storage, away from moisture
Powder -80°C 2 years -20°C 1 year * In solvent : -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture)
Solvent & Solubility
DMSO : 5 mg/mL (2.11 mM; Need ultrasonic; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO)
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture). When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture). When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
Purity & Documentation
-
Data Sheet (276 KB)
-
SDS (252 KB)
- English - EN (252 KB)
- Français - FR (252 KB)
- Deutsch - DE (252 KB)
- Norwegian - NO (252 KB)
- Español - ES (252 KB)
- Swedish - SV (252 KB)
- Italian - IT (252 KB)
- Korean - KR (252 KB)
- Portuguese - PT (252 KB)
-
Handling Instructions (2659 KB)
References
[1]. Adachi T, et al. A novel Lyn-binding peptide inhibitor blocks eosinophil differentiation, survival, and airway eosinophilic inflammation. J Immunol. 1999;163(2):939-946. [Content Brief]
[2]. Adachi T, et al. The mapping of the Lyn kinase binding site of the common beta subunit of IL-3/granulocyte-macrophage colony-stimulating factor/IL-5 receptor. J Immunol. 1999;162(3):1496-1501. [Content Brief]
Complete Stock Solution Preparation Table
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture). When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
| Optional Solvent | Concentration Solvent Mass | 1 mg | 5 mg | 10 mg | 25 mg |
|---|---|---|---|---|---|
| DMSO | 1 mM | 0.4218 mL | 2.1089 mL | 4.2178 mL | 10.5446 mL |
Lyn peptide inhibitor Related Classifications
HY-P1111 Related Classifications
Powered by Bioz